Search details
1.
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Nature
; 629(8013): 919-926, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38589574
2.
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
Mol Oncol
; 18(6): 1552-1570, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38348572
3.
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer.
Drugs Context
; 112022.
Article
in English
| MEDLINE | ID: mdl-36452878
4.
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine.
Nat Commun
; 13(1): 1503, 2022 03 21.
Article
in English
| MEDLINE | ID: mdl-35314684
5.
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 28(8): 1640-1650, 2022 04 14.
Article
in English
| MEDLINE | ID: mdl-35091439
6.
Exploiting orthologue diversity for systematic detection of gain-of-function phenotypes.
BMC Genomics
; 9: 254, 2008 May 29.
Article
in English
| MEDLINE | ID: mdl-18510758
7.
YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors.
Nat Cancer
; 4(6): 784-786, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37369836
8.
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.
Oncotarget
; 8(24): 38193-38213, 2017 Jun 13.
Article
in English
| MEDLINE | ID: mdl-28445144
9.
Four individually druggable MET hotspots mediate HGF-driven tumor progression.
J Clin Invest
; 124(7): 3172-86, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24865428
Results
1 -
9
de 9
1
Next >
>>